Brii Biosciences Limited (2137.HK)
Develops drug treatments for hepatitis B, HIV, and bacterial infections in China and the U.S.
0.96+0.00%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-49.2%
The outlook
BRII trades at 0.96 HKD, sitting well below both its 50- and 200-day moving averages and near the lower end of its 52-week range. Analyst coverage appears limited. The current positioning reflects weak near-term momentum and a bearish technical setup.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range3% of the way from its 52-week low to high
Market cap
$692.3M
52-wk high
2.54
52-wk low
0.91
50-day avg
1.06
200-day avg
1.43
Trailing P/E
—